Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-dependent anion-selective channel protein 1 (VDAC1), frequently referred to as mitochondrial porin, is a 30 kDa beta-barrel protein located in the outer mitochondrial membrane. It functions as the primary conduit for the exchange of ions and essential metabolites, such as ATP, ADP, and respiratory substrates, between the mitochondria and the cytoplasm, thereby acting as a gatekeeper of mitochondrial metabolism (1.2.1, 1.2.3). In cancer cells, VDAC1 is typically overexpressed and associates with hexokinase to promote the Warburg effect and suppress apoptosis, making its inhibition or the disruption of its protein-protein interactions a viable strategy for inducing tumor cell death (1.3.2, 1.3.5). Conversely, in neurodegenerative conditions like Alzheimer's and Parkinson's diseases, VDAC1 is implicated in pathological mitochondrial permeabilization and cell death, where its modulation may offer neuroprotective benefits (1.2.4, 1.3.1). Drugs targeting VDAC1, such as erastin and VBIT-4, aim to either induce ferroptosis or prevent harmful oligomerization, highlighting its versatility as a therapeutic target across multiple disease areas (1.3.3, 1.3.4).
Modulation of mitochondrial outer membrane permeability, inhibition of VDAC1 oligomerization, and disruption of VDAC1-hexokinase interactions to regulate metabolic flux and apoptosis.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-dependent anion-selective channel protein 1 (VDAC1) (VDAC1).